10 Best Performing American Stocks in June 2026

8. Biohaven Ltd. (NYSE:BHVN)

On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim for refractory focal epilepsy. Opakalim is Biohaven’s selective Kv7.2/7.3 channel activator, and top-line results from the study are expected in 2H 2026.

On June 29, Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves’ disease. BHV-1300 is the first MoDE extracellular protein degrader, described by the company as a novel small molecule IgG1, 2, and 4 degrader that uses the body’s clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves’ disease.

On June 26, Deutsche Bank raised the firm’s price target on Biohaven to $20 from $15 and kept a Buy rating on the shares. Deutsche Bank said the company’s troriluzole in spinocerebellar ataxia could be the next beneficiary of recent FDA reversals.

Biohaven Ltd. (NYSE:BHVN) focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

1281292 - 11759070 - 1